Adamis Pharma (ADMP)
NASDAQ:ADMP

Adamis Pharma (ADMP) Stock Price & Analysis

1,085 Followers

ADMP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.12 - $0.73
Previous Close$0.23
Volume774.44K
Average Volume (3M)623.49K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$2.42M
Total Debt (Recent Filing)$432.02K
Price to Earnings (P/E)-0.5
Beta0.73
Next EarningsMar 30, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-0.48
Shares Outstanding149,983,265
R-Squared0.05
Standard Deviation0.33
10 Day Avg. Volume497,574
30 Day Avg. Volume623,485
Price to Book (P/B)10.57
Price to Sales (P/S)12.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha-0.02
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ADMP FAQ

What was Adamis Pharma’s price range in the past 12 months?
Adamis Pharma lowest stock price was $0.12 and its highest was $0.73 in the past 12 months.
    What is Adamis Pharma’s market cap?
    Currently, no data Available
    When is Adamis Pharma’s upcoming earnings report date?
    Adamis Pharma’s upcoming earnings report date is Mar 30, 2023 which is in 55 days.
      How were Adamis Pharma’s earnings last quarter?
      Adamis Pharma released its earnings results on Nov 14, 2022. The company reported -$0.03 earnings per share for the quarter, the consensus estimate of -$0.03 by $0.
        Is Adamis Pharma overvalued?
        According to Wall Street analysts Adamis Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Adamis Pharma pay dividends?
          Adamis Pharma does not currently pay dividends.
          What is Adamis Pharma’s EPS estimate?
          Adamis Pharma’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Adamis Pharma have?
          Adamis Pharma has 149,983,260 shares outstanding.
            What happened to Adamis Pharma’s price movement after its last earnings report?
            Adamis Pharma reported an EPS of -$0.03 in its last earnings report, expectations of -$0.03. Following the earnings report the stock price went up 22.222%.
              Which hedge fund is a major shareholder of Adamis Pharma?
              Among the largest hedge funds holding Adamis Pharma’s share is Greenlight Capital Inc. It holds Adamis Pharma’s shares valued at N/A.

                ---

                Adamis Pharma Stock Smart Score

                4
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -63.02%
                12-Months-Change

                Fundamentals

                Return on Equity
                Trailing 12-Months
                Asset Growth
                -73.07%
                Trailing 12-Months
                The Adamis Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Adamis Pharma

                Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Elite Pharmaceuticals
                Cumberland Pharmaceuticals
                Item 9 Labs
                Akari Therapeutics
                Nutriband

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis